Transparency in clinical trials is continually changing, and to stay on top of the news, TrialAssure brings a weekly round-up of some of the key stories surrounding disclosures in clinical trials. This week’s stories are as follows:
Simple yet practical analysis of ClinicalTrials.gov – Medium, Towards Data Science
Clinical trials specialist and data scientist Glib Radchenko delves into ClinicalTrials.gov’s data. From mapping where most clinical trials occur to comparing similar interests among drug companies, Radchenko displays interesting visualizations to help interpret the registry’s complex data. These insights help illustrate yet another way in which structured, transparent clinical data provides value.
See Radchenko’s data visualizations on Towards Data Science
China’s clinical trial shake-up – PMLive
The Chinese clinical trial sector is growing with a steady increase of US government-registered trials on ClinicalTrials.gov. Of all the currently enrolling trials registered on ClinicalTrials.gov, 9 percent have a site in China, a marked increase from recent years. This rapidly-growing drug development industry can be attributed to a combination of streamlined process reforms and elevated standards, including rules for transparency reporting on www.chinadrugtrials.org.cn.
Read the full story by Nick Taylor.
Journal editors see improvement in transparency of industry-sponsored publications – Journal of Current Medical Research and Opinion
A new study published in the Journal of Current Medical Research and Public Opinion showed that journal editors see an improvement in transparency and credibility of industry-sponsored publications. The researchers surveyed 293 journal editors and asked them to rank their perceptions of several transparency and credibility topics.
Access the full study here.